CD274 and collecting duct carcinoma: Similar to patients with metastatic urothelial carcinoma, these patients may be treated with dose-dense MVAC and postplatinum anti-PD1 or anti-PDL1 agents, although the activity of these regimens, specifically for collecting duct carcinoma, is lacking (recommendation level D) (Oudard et al. 2007; Zisman et al. 2002).